within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01M_QuinoloneAntibacterials.J01MA24_Levonadifloxacin;

model Levonadifloxacin
  extends Pharmacolibrary.Drugs.ATC.J.J01MA24;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J01MA24</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Levonadifloxacin is a broad-spectrum, novel benzoquinolizine fluoroquinolone antibiotic used primarily for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital-acquired pneumonia. It is effective against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA). Levonadifloxacin has been approved for clinical use in India.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult subjects following intravenous administration.</p><h4>References</h4><ol><li><p>Bhagwat, SS, Nandanwar, M, Kansagara, A, Patel, A, Takalkar, S, Chavan, R, Periasamy, H, Yeole, R, Deshpande, PK, Bhavsar, S, Bhatia, A, Ahdal, J, Jain, R, &amp; Patel, M (2019). Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence. <i>Drug design, development and therapy</i> 13 4351–4365. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S229882&quot;>10.2147/DDDT.S229882</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31920285/&quot;>https://pubmed.ncbi.nlm.nih.gov/31920285</a></p></li><li><p>Mehta, Y, Mishra, KC, Paliwal, Y, Rangappa, P, Sinha, S, &amp; Bhapkar, S (2022). Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin. <i>Critical care research and practice</i> 2022 2668199–None. DOI:<a href=&quot;https://doi.org/10.1155/2022/2668199&quot;>10.1155/2022/2668199</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36785544/&quot;>https://pubmed.ncbi.nlm.nih.gov/36785544</a></p></li><li><p>Bhatia, A, Mastim, M, Shah, M, Gutte, R, Joshi, P, Kumbhar, D, Periasamy, H, Palwe, SR, Chavan, R, Bhagwat, S, Patel, M, Llorens, L, &amp; Friedland, HD (2020). Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Openlabel, Randomized Study. <i>The Journal of the Association of Physicians of India</i> 68(8) 30–36. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32738837/&quot;>https://pubmed.ncbi.nlm.nih.gov/32738837</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Levonadifloxacin;
